Curated News
By: NewsRamp Editorial Staff
September 16, 2025
Nascent Pharma Holdings Completes Corporate Rebranding with New Trading Symbol
TLDR
- Nascent Pharma Holdings gains a clearer market identity with its new NASC symbol, potentially enhancing investor recognition and competitive positioning in the pharmaceutical IP sector.
- Nascent Pharma Holdings completed a name and symbol change to NASC effective September 16, 2025, following its 2024 reorganization as the parent company of Can B Corp.
- This corporate restructuring supports Nascent Pharma's mission to advance cannabis-based medical research, potentially leading to new treatments that improve patient health outcomes.
- Nascent Pharma Holdings now trades as NASC, reflecting its focus on innovative cannabis extract patents that could shape future pharmaceutical developments.
Impact - Why it Matters
This rebranding signals Nascent Pharma's strategic positioning in the emerging cannabis pharmaceutical market, which is projected to reach $50 billion globally by 2025. For investors, the name and symbol change provides clearer market identification and reflects the company's evolution from a general cannabis company to a focused pharmaceutical IP holder. The patent-protected cannabis extraction technologies could lead to breakthrough medical treatments, potentially addressing conditions like chronic pain, epilepsy, and inflammation. As regulatory barriers around cannabis research continue to ease, companies like Nascent Pharma are positioned to capitalize on the growing acceptance of cannabis-derived medicines, making this development significant for both healthcare innovation and investment opportunities.
Summary
Nascent Pharma Holdings, Inc. (formerly Can B Corp.) has officially completed its corporate rebranding, with the Financial Industry Regulatory Authority approving the company's name change and new trading symbol "NASC" effective September 16, 2025. This significant transition follows the holding company reorganization completed in October 2024, where Nascent Pharma Holdings became the parent entity of Can B Corp. The company's common stock now trades under the new symbol with updated CUSIP number 63108T105, marking a fresh identity for investors and stakeholders.
The Florida-based pharmaceutical intellectual property company specializes in maximizing the value of its cannabis patent portfolios, holding two issued patents registered with the US Patent and Trademark Office. These patents cover innovative cannabis extracts and methods of preparation, focusing on both composition and therapeutic applications. Investors and media can find the original release on www.newmediawire.com, which provides comprehensive details about this corporate evolution and the company's forward-looking strategy in the rapidly growing cannabis pharmaceutical sector.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Nascent Pharma Holdings Completes Corporate Rebranding with New Trading Symbol
